Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Idera Pharmaceuticals, Inc.
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125. Patients will proceed through a screening period, treatment period, and follow-up period of approximately 4 months' duration. There will be 4 dose cohorts including active drug and placebo dosing.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HCV-positive
Nonresponder to standard-dose pegylated interferon-α-2a or -α-2b in combination with standard-dose ribavirin
You may not be if
Human immunodeficiency virus (HIV)or hepatitis B surface antigen (HbsAg)
Inadequate bone marrow, liver, and renal function
Treatment with any IFN (interferon)-based or other experimental or antiviral therapies within 30 days
Other significant medical diseases
Known alcohol or drug abuse within the past 12 months
Clareo Health | Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
